BHCM
LRMR icon

Brevan Howard Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Brevan Howard Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,880
Closed -$68.5K – 1935
2025
Q1 		$68.5K Buy
+31,880
New +$101K ﹤0.01% 1075

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Brevan Howard Capital Management's LRMR Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 31,880 shares — an estimated $68.5K sold.

Brevan Howard Capital Management first reported a position in LRMR in Q1 2025 and held it in 1 quarter. The position peaked at $68.5K in Q1 2025. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Brevan Howard Capital Management reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 31,880 Larimar Therapeutics shares in Q2 2025, an estimated $68.5K.
  • Brevan Howard Capital Management first reported a position in Larimar Therapeutics in Q1 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Larimar Therapeutics position peaked at $68.5K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.